MX2023005654A - Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza. - Google Patents
Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza.Info
- Publication number
- MX2023005654A MX2023005654A MX2023005654A MX2023005654A MX2023005654A MX 2023005654 A MX2023005654 A MX 2023005654A MX 2023005654 A MX2023005654 A MX 2023005654A MX 2023005654 A MX2023005654 A MX 2023005654A MX 2023005654 A MX2023005654 A MX 2023005654A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies against
- neutralizing antibodies
- against influenza
- broadly neutralizing
- influenza neuraminidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117448P | 2020-11-23 | 2020-11-23 | |
| US202063123424P | 2020-12-09 | 2020-12-09 | |
| US202163197160P | 2021-06-04 | 2021-06-04 | |
| US202163261463P | 2021-09-21 | 2021-09-21 | |
| PCT/US2021/060155 WO2022109309A1 (en) | 2020-11-23 | 2021-11-19 | Broadly neutralizing antibodies against influenza neuraminidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005654A true MX2023005654A (es) | 2023-07-31 |
Family
ID=79021106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005654A MX2023005654A (es) | 2020-11-23 | 2021-11-19 | Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240092876A1 (https=) |
| EP (1) | EP4247495A1 (https=) |
| JP (1) | JP2023551668A (https=) |
| KR (1) | KR20230137293A (https=) |
| AU (1) | AU2021381778A1 (https=) |
| CA (1) | CA3199023A1 (https=) |
| CL (1) | CL2023001462A1 (https=) |
| CO (1) | CO2023007527A2 (https=) |
| IL (1) | IL302963A (https=) |
| MX (1) | MX2023005654A (https=) |
| PH (1) | PH12023551390A1 (https=) |
| TW (1) | TW202229329A (https=) |
| WO (1) | WO2022109309A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025522295A (ja) * | 2022-05-23 | 2025-07-15 | ヒューマブス・バイオメッド・ソシエテ・アノニム | インフルエンザノイラミニダーゼに対する広域中和抗体 |
| AU2023358546A1 (en) * | 2022-10-14 | 2025-05-29 | Longhorn Vaccines And Diagnostics, Llc | Vaccines and antibodies for the treatment and prevention of microbial infections |
| WO2026021428A1 (en) * | 2024-07-23 | 2026-01-29 | Westlake University | Anti-neuraminidase antibodies and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7803C (https=) | ||||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| ATE492562T1 (de) | 2003-09-24 | 2011-01-15 | Kyowa Hakko Kirin Co Ltd | Rekombinanter antikörper gegen humanen insulin- like growth factor |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| WO2016090170A1 (en) * | 2014-12-05 | 2016-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A potent anti-influenza a neuraminidase subtype n1 antibody |
| EP3294774B1 (en) | 2015-05-13 | 2024-08-28 | Zumutor Biologics, Inc. | Afucosylated protein, cell expressing said protein and associated methods |
| US11254733B2 (en) * | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| AU2018334886B2 (en) | 2017-09-22 | 2025-06-26 | WuXi Biologics Ireland Limited | Novel bispecific polypeptide complexes |
| CA3096703A1 (en) * | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
-
2021
- 2021-11-19 AU AU2021381778A patent/AU2021381778A1/en not_active Abandoned
- 2021-11-19 EP EP21830556.3A patent/EP4247495A1/en active Pending
- 2021-11-19 US US18/253,385 patent/US20240092876A1/en active Pending
- 2021-11-19 PH PH1/2023/551390A patent/PH12023551390A1/en unknown
- 2021-11-19 TW TW110143246A patent/TW202229329A/zh unknown
- 2021-11-19 MX MX2023005654A patent/MX2023005654A/es unknown
- 2021-11-19 KR KR1020237021242A patent/KR20230137293A/ko active Pending
- 2021-11-19 IL IL302963A patent/IL302963A/en unknown
- 2021-11-19 CA CA3199023A patent/CA3199023A1/en active Pending
- 2021-11-19 WO PCT/US2021/060155 patent/WO2022109309A1/en not_active Ceased
- 2021-11-19 JP JP2023531064A patent/JP2023551668A/ja active Pending
-
2023
- 2023-05-22 CL CL2023001462A patent/CL2023001462A1/es unknown
- 2023-06-07 CO CONC2023/0007527A patent/CO2023007527A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022109309A9 (en) | 2022-09-01 |
| KR20230137293A (ko) | 2023-10-04 |
| EP4247495A1 (en) | 2023-09-27 |
| AU2021381778A9 (en) | 2025-01-09 |
| CL2023001462A1 (es) | 2023-10-20 |
| IL302963A (en) | 2023-07-01 |
| CA3199023A1 (en) | 2022-05-27 |
| US20240092876A1 (en) | 2024-03-21 |
| PH12023551390A1 (en) | 2023-12-04 |
| AU2021381778A1 (en) | 2023-06-22 |
| TW202229329A (zh) | 2022-08-01 |
| WO2022109309A1 (en) | 2022-05-27 |
| JP2023551668A (ja) | 2023-12-12 |
| CO2023007527A2 (es) | 2023-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006462A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| EP4245373A3 (en) | Antibodies against sars-cov-2 | |
| PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
| PH12023551390A1 (en) | Broadly neutralizing antibodies against influenza neuraminidase | |
| PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| PH12022500020A1 (en) | Antibodies against sars-cov-2 | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| WO2018187706A3 (en) | Anti-influenza b virus neuraminidase antibodies and uses thereof | |
| WO2018170351A8 (en) | Anti-phf-tau antibodies and uses thereof | |
| AU2017297757A1 (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| WO2019165122A8 (en) | Neutralizing antibodies to hiv-1 env and their use | |
| MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| PL422231A1 (pl) | Komórki immunologiczne CAR do leczenia nowotworów | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
| EA202090559A1 (ru) | Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| PH12021552903A1 (en) | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof | |
| WO2021212049A3 (en) | Anti-sars-cov-2 monoclonal antibodies | |
| PH12022553035A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| MX2022014598A (es) | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. | |
| WO2017192946A8 (en) | MONOCLONAL DNA ANTIBODIES TARGETING INFLUENZA VIRUS | |
| MX2023005653A (es) | Anticuerpos contra los virus de la influenza a. | |
| WO2023230445A3 (en) | Broadly neutralizing antibodies against influenza neuraminidase |